Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report.
Fabrizio MartoraTeresa BattistaLuca PotestioAntonio PortarapilloNello TommasinoMatteo MegnaPublished in: Clinical, cosmetic and investigational dermatology (2024)
Managing HS has long posed a significant challenge for dermatologists. Adalimumab stands as the sole biologic drug sanctioned for HS, receiving approval in 2015 as an anti-tumor necrosis factor (TNF)-α drug. Real-life evidence over the years has debated its efficacy, suggesting a success rate hovering around 70%. However, the variability in existing treatments and the chronic-recurrent nature of the condition make its treatment and management exceedingly challenging. Hence, identifying new therapeutic targets for HS in the future becomes imperative. Recently, on October 31, 2023, the FDA approved secukinumab for moderate-severe HS, marking a significant development. There has been substantial discourse on the potential of anti-interleukin-23 drugs as new therapeutic avenues for treating HS in recent years. Here, we report a case of 17-year-old man successfully treated with Guselkumab. The results were confirmed at week 52.
Keyphrases
- rheumatoid arthritis
- hidradenitis suppurativa
- end stage renal disease
- drug induced
- chronic kidney disease
- newly diagnosed
- mental health
- young adults
- ankylosing spondylitis
- prognostic factors
- emergency department
- peritoneal dialysis
- clinical trial
- high intensity
- combination therapy
- current status
- ulcerative colitis
- climate change